Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Monte Rosa Therapeutics (NASDAQ:GLUE) had its price target boosted by analysts at Wells Fargo & Company from $22.00 to $30.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price would indicate a potential upside of 23.04% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings restated a “sell (d)” rating on shares of Monte Rosa Therapeutics in a report on Monday, December 29th. Wedbush restated an “outperform” rating and issued a $37.00 target price on shares of Monte Rosa Therapeutics in a research note on Wednesday. Jefferies Financial Group reaffirmed a “buy” rating and set a $31.00 price target on shares of Monte Rosa Therapeutics in a report on Wednesday. Guggenheim boosted their price objective on shares of Monte Rosa Therapeutics from $16.00 to $34.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Zacks Research raised shares of Monte Rosa Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $30.20.

Monte Rosa Therapeutics Price Performance

NASDAQ GLUE traded up $1.10 during trading hours on Thursday, hitting $24.38. The company had a trading volume of 1,177,444 shares, compared to its average volume of 5,356,217. The firm’s 50 day moving average is $15.53 and its 200 day moving average is $9.50. Monte Rosa Therapeutics has a fifty-two week low of $3.50 and a fifty-two week high of $25.77. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of 76.17 and a beta of 1.60.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its earnings results on Thursday, November 6th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.06. Monte Rosa Therapeutics had a return on equity of 8.28% and a net margin of 11.54%.The company had revenue of $12.77 million during the quarter, compared to the consensus estimate of $7.37 million. On average, equities analysts anticipate that Monte Rosa Therapeutics will post -1.49 EPS for the current year.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC bought a new position in shares of Monte Rosa Therapeutics during the fourth quarter worth about $30,000. Vestal Point Capital LP acquired a new position in Monte Rosa Therapeutics during the 3rd quarter valued at about $5,928,000. Scientech Research LLC bought a new position in Monte Rosa Therapeutics in the 3rd quarter worth about $120,000. Prelude Capital Management LLC bought a new position in Monte Rosa Therapeutics in the 3rd quarter worth about $76,000. Finally, Millennium Management LLC increased its stake in shares of Monte Rosa Therapeutics by 588.4% in the third quarter. Millennium Management LLC now owns 444,939 shares of the company’s stock valued at $3,297,000 after purchasing an additional 380,308 shares during the period. 79.96% of the stock is owned by institutional investors and hedge funds.

More Monte Rosa Therapeutics News

Here are the key news stories impacting Monte Rosa Therapeutics this week:

• Positive Sentiment: Interim Phase 1 data — MRT-8102 produced an 85% median reduction in high‑sensitivity CRP after 4 weeks and 94% of subjects hit CRP <2 mg/L; NEK7 degradation, IL‑1β/IL‑6 reductions and a favorable safety profile were reported. This validates the NEK7 approach and supports planned Phase 2 work, driving enthusiasm for the stock. GlobeNewswire: Interim Phase 1 Data
• Positive Sentiment: Major media and analyst reaction — Coverage from Investing.com and MSN picked up the data, and Zacks upgraded GLUE to a Strong Buy, a move that can attract momentum buyers and retail interest. Investing.com: Stock Surges After Data Zacks: Upgrade to Strong Buy
• Neutral Sentiment: Industry/analyst commentary — Seeking Alpha and QuiverQuant provide deeper reads on competitive positioning and platform validation; useful for medium-term thesis but less likely to move price alone. Seeking Alpha: Competitive MRT-8102 Results
• Negative Sentiment: Proposed $200M public offering — Monte Rosa launched an underwritten offering of common stock and pre‑funded warrants to raise $200M. This raises near‑term dilution risk and can weigh on the stock despite positive clinical news. GlobeNewswire: Proposed Public Offering
• Negative Sentiment: Interim-data and timing risk — The results are interim and the company’s planned Phase 2/expanded readouts are months away (GFORCE-1 readout H2 2026). Future trial outcomes, regulatory steps, or safety findings could reverse sentiment. GlobeNewswire: Interim Data & Forward-Looking Statements

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.